Could high plasma bikunin predict a favorable outcome in ovarian cancer?
McIntosh
Martin
M
Fred Hutchinson Cancer Research Center and Computational Proteomics Laboratory, Seattle, WA 98109, USA. mmcintosh@fhcrc.org
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008562:Membrane Glycoproteins / Q000097:blood* / Q000378:metabolism; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood* / Q000401:mortality* / Q000473:pathology*; D011336:Probability; D011379:Prognosis; D011446:Prospective Studies; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D015996:Survival Rate; D014360:Trypsin Inhibitor, Kunitz Soybean / Q000097:blood* / Q000378:metabolism
D014408:Biomarkers, Tumor; D008562:Membrane Glycoproteins; C109148:SPINT2 protein, human; D014360:Trypsin Inhibitor, Kunitz Soybean